![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NICE Recommends Tukysa for HER2-Positive Breast Cancer
NICE Recommends Tukysa for HER2-Positive Breast Cancer
The UK’s National Institute for Health and Care Excellence (NICE) has issued a draft guidance recommending that the National Health Service provide Seagen’s Tukysa (tucatinib) as a treatment for patients with HER2-positive breast cancer.
NICE endorsed the drug in combination with Roche’s Herceptin (trastuzumab) and Xeloda (capecitabine) for breast cancer patients who have previously received two or more anti-HER2 treatments.
The institute previously rejected Tukysa over cost concerns. However, this time Seagen offered a confidential discount and provided additional efficacy data, especially in patients suffering from brain metastases.
NICE is expected to issue final guidance in March.
Upcoming Events
-
21Oct